Compare First Trust Cloud Computing ETF (SKYY) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Trust Cloud Computing ETF vs Twist Bioscience Corp — how do they compare? First Trust Cloud Computing ETF trades at $174.89 (market cap $3.47B), while Twist Bioscience Corp trades at $159.78 (market cap $10.08B). The key difference: Twist Bioscience Corp is far larger — about 2.9× First Trust Cloud Computing ETF's market cap, and First Trust Cloud Computing ETF is trading nearer its 52-week high, Twist Bioscience Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold First Trust Cloud Computing ETF for 85 Days and Twist Bioscience Corp for 27 Days on average.
| SKYY | TWST | |
|---|---|---|
Market Cap | $3.47B | $10.08B |
Volume | 176,159 | 4,229,037 |
52-Week High | $174.89 | $205.00 |
52-Week Low | $104.16 | $25.45 |
Typical Hold Time | 85 Days | 27 Days |
Sector | — | Health |
Enterprise Value | — | $10.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
First Trust Cloud Computing ETF (SKYY) trades at $170.14, down 0.37% on the day but near its 52-week high of $169.41. Technical indicators show a bullish trend with strong moving average support, while oscillators remain neutral. The ETF provides diversified exposure to cloud computing companies benefiting from AI adoption and digital transformation trends, with recent articles highlighting strong sector momentum.
The outlook remains positive given cloud computing's structural growth drivers, though valuation metrics are unavailable for analysis. Key risks include sector concentration and market volatility, while institutional activity shows mixed positioning. The ETF's focus on cloud infrastructure positions it well for continued AI-driven demand.
TWST trades at $152.05, down 2.31% today, with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported Q2 2026 EPS of -$0.56, missing expectations, continuing a trend of losses despite revenue growth to $376.57M in 2025. Recent news highlights a partnership with Lilly TuneLab for AI-driven drug discovery, driving investor optimism.
Outlook remains speculative with high valuation multiples (P/S 21.5, P/B 22.62) and persistent losses, but analyst consensus is bullish (73% buy ratings) with a $145.20 price target. Key risks include cash burn, competitive pressures, and reliance on AI-driven growth catalysts for profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About First Trust Cloud Computing ETF
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is designed to track the performance of companies involved in the cloud computing industry.
Read more on SKYY →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
